Literature DB >> 16323417

NK cell receptors involved in the response to human cytomegalovirus infection.

M Gumá1, A Angulo, M López-Botet.   

Abstract

Human cytomegalovirus (HCMV) infection is a paradigm of the complexity reached by host-pathogen interactions. To avoid recognition by cytotoxic T lymphocytes (CTL) HCMV inhibits the expression of HLA class I molecules. As a consequence, engagement of inhibitory killer immunoglobulin-like receptors (KIR), CD94/NKG2A, and CD85j (ILT2 or LIR-1) natural killer cell receptors (NKR) specific for HLA class I molecules is impaired, and infected cells become vulnerable to an NK cell response driven by activating receptors. In addition to the well-defined role of the NKG2D lectin-like molecule, the involvement of other triggering receptors (i.e., activating KIR, CD94/NKG2C, NKp46, NKp44, and NKp30) in the response to HCMV is being explored. To escape from NK cell-mediated surveillance, HCMV interferes with the expression of NKG2D ligands in infected cells. In addition, the virus may keep NK inhibitory receptors engaged preserving HLA class I molecules with a limited role in antigen presentation (i.e., HLA-E) or, alternatively, displaying class I surrogates. Despite considerable progress in the field, a number of issues regarding the involvement of NKR in the innate immune response to HCMV remain uncertain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16323417     DOI: 10.1007/3-540-27743-9_11

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  25 in total

1.  NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus.

Authors:  Jiangao Zhu; Xiaopei Huang; Yiping Yang
Journal:  J Immunol       Date:  2010-11-12       Impact factor: 5.422

Review 2.  Are circadian rhythms the code of hypothalamic-immune communication? Insights from natural killer cells.

Authors:  Alvaro Arjona; Dipak K Sarkar
Journal:  Neurochem Res       Date:  2007-10-27       Impact factor: 3.996

Review 3.  Immune evasion of natural killer cells by viruses.

Authors:  Stipan Jonjić; Marina Babić; Bojan Polić; Astrid Krmpotić
Journal:  Curr Opin Immunol       Date:  2008-02       Impact factor: 7.486

4.  The SCHOOL of nature: III. From mechanistic understanding to novel therapies.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-06-11

Review 5.  Evasion from NK cell-mediated immune responses by HIV-1.

Authors:  Stephanie Jost; Marcus Altfeld
Journal:  Microbes Infect       Date:  2012-05-21       Impact factor: 2.700

6.  NK cell-extrinsic IL-18 signaling is required for efficient NK-cell activation by vaccinia virus.

Authors:  Joshua D Brandstadter; Xiaopei Huang; Yiping Yang
Journal:  Eur J Immunol       Date:  2014-06-17       Impact factor: 5.532

7.  Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection.

Authors:  Jennifer Martinez; Xiaopei Huang; Yiping Yang
Journal:  PLoS Pathog       Date:  2010-03-12       Impact factor: 6.823

Review 8.  Expansion, maintenance, and memory in NK and T cells during viral infections: responding to pressures for defense and regulation.

Authors:  Christine A Biron
Journal:  PLoS Pathog       Date:  2010-03-26       Impact factor: 6.823

9.  Activating receptors promote NK cell expansion for maintenance, IL-10 production, and CD8 T cell regulation during viral infection.

Authors:  Seung-Hwan Lee; Kwang-Sin Kim; Nassima Fodil-Cornu; Silvia M Vidal; Christine A Biron
Journal:  J Exp Med       Date:  2009-08-31       Impact factor: 14.307

10.  KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C.

Authors:  Thorsten Graef; Achim K Moesta; Paul J Norman; Laurent Abi-Rached; Luca Vago; Anastazia M Older Aguilar; Michael Gleimer; John A Hammond; Lisbeth A Guethlein; David A Bushnell; Philip J Robinson; Peter Parham
Journal:  J Exp Med       Date:  2009-10-26       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.